Zacks: Analysts Expect Stemline Therapeutics Inc (NASDAQ:STML) Will Announce Quarterly Sales of $8.84 Million
Equities research analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to post sales of $8.84 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Stemline Therapeutics’ earnings, with the lowest sales estimate coming in at $5.55 million and the highest estimate coming in at $11.75 million. Stemline Therapeutics posted sales of $500,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 1,668%. The business is expected to report its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Stemline Therapeutics will report full year sales of $41.46 million for the current year, with estimates ranging from $23.80 million to $54.38 million. For the next fiscal year, analysts expect that the company will report sales of $134.32 million, with estimates ranging from $87.36 million to $207.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to analysts’ expectations of $2.61 million.
In other news, CEO Ivan Bergstein sold 10,822 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $15.49, for a total transaction of $167,632.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kenneth Hoberman sold 9,107 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $15.49, for a total transaction of $141,067.43. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,177 shares of company stock valued at $2,236,377. Company insiders own 13.10% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Stemline Therapeutics during the 2nd quarter worth about $67,000. Rhenman & Partners Asset Management AB bought a new stake in shares of Stemline Therapeutics during the 2nd quarter valued at $7,568,000. Metropolitan Life Insurance Co NY boosted its holdings in shares of Stemline Therapeutics by 56.7% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 4,835 shares in the last quarter. MetLife Investment Advisors LLC boosted its holdings in shares of Stemline Therapeutics by 54.6% during the 1st quarter. MetLife Investment Advisors LLC now owns 18,471 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 6,524 shares in the last quarter. Finally, Knott David M boosted its holdings in shares of Stemline Therapeutics by 1.3% during the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 2,000 shares in the last quarter. 77.66% of the stock is owned by institutional investors and hedge funds.
Shares of STML stock traded up $0.39 on Tuesday, hitting $13.41. The stock had a trading volume of 185,880 shares, compared to its average volume of 376,426. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. The firm has a market capitalization of $585.82 million, a price-to-earnings ratio of -4.48 and a beta of 1.33. Stemline Therapeutics has a 1 year low of $7.82 and a 1 year high of $17.85. The firm has a 50 day moving average of $14.25.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Article: What does cost of debt say about a company’s financial health?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.